cyrilzakka/clinical-trials huggingface dataset:
Multidisciplinary Approach for High-risk Patients Leading to Early Diagnosis of Canadians With Heart Failure

In the MAPLE-CHF trial, patients will be screened for HF risk factors using electronic medical records of participating family physicians to identify patients with potentially undiagnosed HF. Participants will then undergo a diagnostic evaluation using a blood sample for a hormone specific to the heart, the natriuretic peptide or NT-proBNP; if elevated, a portable cardiac ultrasound (ECHO) with artificial intelligence (AI) interpretation will be done; both NT-proBNP and ECHO are required for diagnosis in patients with signs and symptoms suggestive of HF. This screening ECHO coupled with AI reading from Us2.ai provides a fast, reliable, and inexpensive report, which is particularly important in our context, where waiting lists for such examinations can reach up to one year.


Eligibility Criteria:
Inclusion Criteria:

Male or female ≥40 years of age informed consent and at least two additional risk factors for HF: coronary artery disease \[either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50% left main stem or \>70% left anterior descending, circumflex or right coronary artery) diabetes type 1 or type 2, persistent or permanent atrial fibrillation, previous ischemic or embolic stroke peripheral arterial disease (previous surgical or percutaneous revascularization or documented stenosis \>50% of major peripheral arterial vessel), chronic kidney disease (estimated glomerular filtration rate \<60mL/min/1.73m2 or eGFR 60-90mL/min/1.73m2 and UACR \>300mg/g), regular loop diuretic use for \>30 days within 12 months COPD (evidenced by one of the following: PFTs showing airway obstruction diagnosis by respiratory physician CT scan reporting presence of emphysema, or treatment with national guideline COPD therapy).

Exclusion Criteria:

Inability to give informed consent e.g., due to significant cognitive impairment, previous diagnosis of heart failure (this is any diagnosis of heart failure with any ejection fraction of any cause) renal replacement therapy, anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.
Invasive Prenatal Testing Decisions in Pregnancy After Infertility

This study will explore the decision-making experiences of women who are currently pregnant following a period of infertility on whether or not to undergo an invasive prenatal test (IPT) procedure, such as amniocentesis or chorionic villus sampling. Women who become pregnant after infertility often experience heightened anxiety regarding the outcome of the pregnancy. When choosing whether or not to have IPT they are faced with a complex decision, set in the unique context of a pregnancy that they often perceive as exceptionally precarious.

Women who are pregnant with their first child after a period of infertility and have made a decision regarding whether or not to undergo IPT may be eligible for this study.

Participants complete an online password-protected questionnaire that measures infertility and decision-making variables and explores women's perceptions of the impact of infertility on their IPT decision-making process. The questionnaire covers the following areas:

* Subject's demographic information, such as age, marital status, number of children, education, race, ethnicity
* Subject's infertility history
* Subject's thoughts and feelings about infertility
* Subject's thoughts and concerns about other people's (e.g., husband, doctor, other infertile women) opinions about IPT
* Subject's decision about whether or not to have IPT and her feelings regarding the decision
* The effect of subject's infertility history on her decision to have or not have IPT

Women who are pregnant after infertility often experience heightened anxiety regarding the outcome of the pregnancy. When choosing whether or not to have invasive prenatal testing they are faced with a complex decision, set in the unique context of a pregnancy that they often perceive as exceptionally precious. The proposed study aims to explore the invasive prenatal testing decision-making experiences of women who are pregnant after infertility. A cross-sectional design will be used to investigate relationships between the infertility experience and decisional conflict associated with deciding whether or not to have invasive prenatal testing. Women who are pregnant after infertility will be recruited from online support groups and websites for pregnancy after infertility. Participants will be asked to complete a questionnaire that measures infertility and decision-making variables and elicits their perceptions of the impact of infertility on their IPT decision-making experience. The main outcome measure is decisional conflict.

Eligibility Criteria:
* INCLUSION CRITERIA:

Women.

Self-reported history of infertility.

Currently pregnant.

First pregnancy after period of infertility.

Have been offered IPT during current pregnancy for risk of aneuploidy due to maternal age greater than 35 years, abnormal first or second trimester screening or an ultrasound anomaly.

Have made decision about IPT.

Ability to read and write English.

EXCLUSION CRITERIA:

Men, children.
Valvosoft First-In-Man Study in Severe Symptomatic Aortic Stenosis

This is a prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) - First-In-man

CARDIAWAVE has developed a new non-invasive, real-time image-guided, therapeutic approach to treat patients suffering from Calcified Aortic Stenosis. CARDIAWAVE's Valvosoft device is a new ultrasound therapy based on a disruptive technology involving delivering an extremely precise and focused ultrasound beam to perform a reparative effect on the aortic valve leaflets, softening the valve's tissues, restoring leaflet mobility, and therefore improving the overall clinical status related to the aortic valve stenosis. This is a FIM study

Eligibility Criteria:
Inclusion Criteria:

1. Subjects suffering from severe symptomatic aortic valve stenosis (including subjects with a bicuspid valve).
2. Patient is not eligible for TAVR/SAVR .
3. Age ≥18 years.
4. Subjects who are willing to provide a written informed consent prior to participating in the study.
5. Subjects who can comply with the study follow up or other study requirements.
6. Subject eligible according to Clinical Review Committee

   -

Exclusion Criteria:

1. Subjects with any electrical device implanted.
2. Subjects with unstable arrhythmia not controlled by medical treatment.
3. Subjects with implanted mechanical valve in any position or bio prosthetic valve in aortic position.
4. Subjects with complex congenital heart disease.
5. Chest deformity.
6. Cardiogenic shock.
7. History of heart transplant.
8. Subjects requiring other cardiac surgery procedures (bypass graft surgery, mitral valve procedure, tricuspid valve procedure) within one month after treatment.
9. Thrombus in heart.
10. Acute myocardial infarction (MI), stroke or transient ischemic attack (TIA) within one month prior to enrolment\*.
11. Subjects who are pregnant or nursing.
12. Subjects who are participating in another research study for which the primary endpoint has not been reached.

    -
Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury

Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with moderate \& severe TBI detected on admission by CT scan and GCS score of ≤ 13 who either do not have any other injuries or only have associated minor injuries.

Minor injuries are defined as presence of any of the following:

1. Mild intraperitoneal free fluid (IPFF) observed through abdominal ultrasound.
2. mild lung contusion detected in the chest CT scan.
3. hemothorax or pneumothorax present without accompanying symptoms of hypoxia, tachypnea, or respiratory distress.
4. simple limb fractures.

Exclusion Criteria:

1. Patients on pre-injury beta-blocker therapy.
2. Patients with any bronchospastic conditions.
3. Patients with active acute coronary syndrome.
4. TBI with GCS ≤ 13 with associated major injuries defined as the presence of any of the following:

   1. Moderate \& marked IPFF requiring surgical intervention ( laparotomy ).
   2. moderate \& marked lung contusion, pneumothorax \& hemothorax with accompanying symptoms of hypoxia, tachypnea, lower limbs, or limb amputation.
   3. Compound fracture in the upper or lower limb.
   4. Open Faciomaxillary trauma.
5. Patients with persistent shock (systemic blood pressure \<100 mmHg, base deficit \> 4, or oliguria , HR \< 60 b/min ) after \> one week of admission.
A Global Prospective Observational Registry of Patients With Pompe Disease

This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and infantile-onset pompe disease (IOPD). Both untreated patients and those being treated with an approved therapy for Pompe disease are eligible to participate.

The objectives of the registry are:

* To evaluate the long-term safety of Pompe disease treatments through collection of data that describe the frequency of adverse events (AEs)/serious adverse events (SAEs) occurring in Pompe disease patients
* To evaluate the long-term real-world effectiveness of Pompe disease treatments
* To evaluate the long-term real-world impact of Pompe disease treatments on quality of life (QOL) and patient-reported outcomes (PROs)
* To describe the natural history of untreated Pompe disease


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of LOPD or IOPD based on documented deficiency of GAA enzyme activity and/or GAA genotyping

Exclusion Criteria:

* Patients who are currently receiving investigational therapy for Pompe disease in a clinical trial, a compassionate use program, or an expanded access program (EAP)
A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

To assess the efficacy and safety of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies


Eligibility Criteria:
Inclusion criteria:

1. Patients over 13 years old (complete the elementary school course).
2. Patients had at least two seizures in the past and at least one seizure for the last 3 months before screening.
3. Patients had no antiepileptic drugs for the last 4 months.
4. Women of childbearing age who agree to contraception during participating this clinical trial.

Exclusion criteria:

1. Pregnancy
2. Patients who have progressive neurologic disease
3. Allergy to sulfonamides
4. Use of acetazolamide within a year
5. Hemolytic anemia
6. Patients who have abnormal liver function (GOT or GPT) values more than twice the normal values.
7. Patients who have abnormal renal function (BUN or Creatinine) values more than three times the normal values.
8. Patients who have history of drug or alcohol abuse.
9. Glucose-6-phosphate dehydrogenase deficiency.
10. Patients who were detected with renal stones on KUB (Kidney-Ureter-Bladder) test.
11. Patients who have progressive internal or surgical disease.
12. Patients who have progressive psychiatric disease.
13. Patients who have mental retardation (IQ 70 and less).
14. Patients taking Vit C.
Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)

The goal of this observational study is to continuously assess cerebral autoregulation in patients with subarachnoid hemorrhage (SAH) using cerebral oximetry index (COx) and hemoglobin volume reactivity index (HVx). The main question it aims to answer is: Whether optimal perfusion pressure is dynamic and changes with time in patients with SAH, and that autoregulation is disrupted in patients during the course of SAH, contributing to delayed cerebral ischemia (DCI).


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 to 89 years who are admitted to the Neurological Intensive Care Unit (Neuro ICU) between March 2025 and December 2026 for aneurysmal subarachnoid hemorrhage (SAH).

Exclusion Criteria:

* Patients under 18 years old
* Prisoners
* Pregnant women
* Patients enrolled in concurrent ongoing interventional trial
* Students of UAB
* Employees of UAB
* Patients who undergoes frontal decompression surgery resulting bone flap deficit where NIRS monitoring pads could not be applied.
A Study to Determine the Efficacy of a Denture Adhesive to Seal Out Food Particles From Under the Mandibular Partial Denture

The objective of this study is to evaluate the effectiveness of two denture adhesives at keeping food particles (seeds) from becoming trapped underneath partial denture(s).


Eligibility Criteria:
Inclusion Criteria:

* give written informed consent prior to their participation;
* be 18 years of age or older;
* have a Kennedy Class I or class II partial mandibular denture with a minimum of three consecutive teeth on the prosthesis;
* have a history of food particles getting under their partial, mandibular denture;
* agree not to use any denture adhesive on the day of their study visits, prior to the visit;
* agree to not participate in any other oral/dental product studies during the study;
* be willing to use or not use denture adhesive as instructed during the treatment periods;
* be willing to eat a poppy seed muffin;
* be in good general health as determined by the Investigator/designee based on a review of the medical history/update; and
* have a minimum of 4 total poppy seeds on their mandibular denture base and gingiva after eating the muffin.

Exclusion Criteria:

* present with any disease or conditions that could be expected to interfere with examination procedures or the subject's safe completion of the study;
* self-report that they are allergic to denture adhesives or to the test food (gluten intolerance to muffin or intolerance to poppy seeds); or
* have appliances with intracorneal attachments, crowns with precision attachments or implant overdentures:
* have any condition or medication which, in the opinion of the investigator, is currently causing xerostomia.
BioMonitor Master Study

The BioMonitor is an implantable cardiac monitor used to automatically detect and record episodes of arrhythmia in patients with bradycardia, tachycardia, asystole and atrial fibrillation. The study will be conducted to support regulatory approvals outside of Europe. This BioMonitor Master study is designed to investigate the clinical efficacy and safety of the BioMonitor.


Eligibility Criteria:
Inclusion Criteria:

* Suspected cardiac arrhythmia OR Previous AF diagnosis OR AF diagnosis before or after ablation procedure OR Stroke of unknown origin.

Exclusion Criteria:

* Implanted ICD or cardiac pacemaker
* Allergy to patch electrodes
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.


Eligibility Criteria:
Inclusion Criteria:

Subjects has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding distal interphalangeal joints). Subjects must have at least

1 psoriatic skin lesion. Exclusion Criteria:

• -Subject has known history of active tuberculosis.

* Subject has a planned surgical intervention between baseline and the week 52 evaluation.
* Subject has an active infection or history of infections.
* Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, diabetes, anemia) considered by the Investigator to be clinically significant and uncontrolled.
* Subject has any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.

Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)

• Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.

The long-term goal of this study is to alleviate the occurrence of CIN and to improve chemotherapy treatment outcomes. The identification of associations between CIN and chemotherapy-induced changes in gut microbiome composition profiles will increase our understanding of these mechanisms that underlie CIN. An increased understanding of the underlying mechanisms will provide targets for the development of novel interventions to help alleviate CIN.

Eligibility Criteria:
Inclusion Criteria:

* at least 20 years of age
* last chemotherapy more than 3 years ago
* scheduled to receive either moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies) or immunotherapies/targeted therapies alone that can lead to toxicity symptoms for example, nausea and fatigue.
* Patients receiving chemotherapy and/or immunotherapy treatment at a Mayo Clinic infusion center or an infusion center outside of Mayo Clinic

Exclusion Criteria:

* concurrent radiation therapy
* concurrent antibiotic treatment
* concurrent oncolytic virus treatment
Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old

The purpose of this study is to investigate the influence of the APOE genotype on brain morphology, function and metabolism, related to other factors such as cognitive reserve, cognition and episodic memory, in subjects at greater risk of developing AD.

The purpose of this study is to investigate the influence of age and the APOE genotype on brain morphology and function, in 700 cognitively healthy individuals, 45 to 75 years old, recruited from an ongoing longitudinal cognition study exploring memory and executive functions (ClinicalTrials.gov ID: NCT01835717).

All subjects have been APOE genotyped and underwent a clinical and cognitive assessment. Within this study, the subjects will be submitted to an MRI scanning protocol including morphological and resting state acquisitions. An identical follow-up MRI session will be performed in 2 years' time. The analyses will be focused on detecting the effect of the APOE allelic variants on the change rate of the neuroimaging variables as well as its interaction with aging.

Eligibility Criteria:
Inclusion Criteria:

* Participant included in the study ClinicalTrials.gov ID: NCT01835717
* APOE genotype obtained before MRI acquisition
* Be willing to perform an MRI and agree to a 2 years longitudinal follow up
* Sign informed consent

Exclusion Criteria:

* Contraindication to MRI scanning: claustrophobia, pacemaker, history of ocular cerclage, heart valves, aneurysm clips and carrying any metal prosthesis incompatible with MRI.
* Incidental MRI findings that result in the images not being included in the study.
Clinical Spectrum and Outcome of Poisoning in Children Admitted to the Pediatric Emergency and Intensive Care Units at Sohag University Hospital

Acute poisoning is a major health problem that leads to emergent hospital admission.It has become the main factor that harms children and leads to disability and death of children. Also, it is still a serious issue in developing countries where it represents a common cause of emergency department presentation and admission. Acute poisoning can be divided into two categories (accidental and intentional),accidental poisoning is common in children under five years, whereas intentional poisoning is more common in adolescents, WHO estimated that, in 2016, accidental poisoning caused 106,683 deaths and the loss of 6.3 million years of healthy life.

A study in Romania showed that intentional poisoning is the most common cause of poisoning among teenagers. Females are more vulnerable to suicidal or intentional poisoning than males. Medications, alcohol, and substance abuse are common poisoning agents among teenagers , another study at tertiary Indian hospital, pesticides, pharmaceutical drugs, and household products were the most common types of acute poisoning. Pesticides were reported as a cause of intentional and accidental poisoning. In agricultural areas, people were poisoned accidentally by pesticides that may be used for suicidal attempts because of their availability. Pharmaceutical drugs are also used for intentional poisoning due to the availability of street drugs and over-the-counter medications. Accidental poisoning by household products were observed in children and the most common products are hydrocarbon and naphthalene In Egypt acute poisoning represents a significant proportion of emergency visits of children and young people. This labors a burden on healthcare, society and economy and thus, it drain-s resources and multiplies workload . In fact, it is a preventable cause of morbidity and mortality. Children poisoning is a result of multiple risk factors including social, demographic, and industrial factors. Insufficient public awareness, easy accessibility to poison, negligence of caregivers, technological and industrial advances and even the nature of the environment are of the main causes.


Eligibility Criteria:
Inclusion Criteria:

* All patients admitted to pediatric emergency and intensive care units with claim or suspected to have acute poisoning aged from 1 month Up to 18 years old.

Exclusion Criteria:

* Children with chronic poisoning
* no clear history or clinical picture of definite toxic poison
* incomplete clinical data